<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00538486</url>
  </required_header>
  <id_info>
    <org_study_id>HOT-ACME 1</org_study_id>
    <nct_id>NCT00538486</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients</brief_title>
  <acronym>HOT-ACME</acronym>
  <official_title>Which is the Best Treatment for Non-diabetic Hypertension With Obesity: Telmisartan, Amlodipine or Candesartan, Alone or Plus MEtformin? (HOT-ACME 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The epidemic of obesity is associated with a considerable rise in the incidence of the
      metabolic syndrome, type 2 diabetes mellitus, and hypertension. Insulin resistance plays an
      important role in the pathogenesis of obesity related hypertension. These patients are at
      high risk to suffer from cardiovascular events. However, current guidelines for treatment of
      hypertension do not provide specific recommendation for the pharmacotherapy of obese
      hypertensive patients due to lack of prospective randomized intervention studies in
      non-diabetic obese hypertensive patients.

      Aside from their antihypertensive effects, angiotensin II receptor blockers (ARB) were shown
      to improve insulin sensitivity. Furthermore, metformin is commonly used to treat the obese
      type 2 diabetes mellitus. Metformin can also lower body weight and increase insulin
      sensitivity. In a prospective, double-blind, double-dummy, randomized, parallel-group study,
      we will evaluate the effects of ARB (telmisartan and candesartan) or amlodipine combination
      with metformin on weight gain, visceral fat, and metabolic parameters in obese hypertensive
      patients without diabetes mellitus compared with obese hypertensives on ARB or amlodipine
      treatment alone. This study will help to develop future comprehensive treatment strategies
      and guidelines for obesity related hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Baseline, 24 weeks(End of trial)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic profiles, including lipid profile and blood glucose</measure>
    <time_frame>Baseline, 24 weeks(End of trial)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abdominal fat assessed by CT</measure>
    <time_frame>Baseline, 24 weeks(End of trial)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obesity parameters, including waist circumference (WC) and body mass index (BMI)</measure>
    <time_frame>Baseline, 24 weeks(End of trial)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance assessed by fasting serum insulin and HOMA-IR</measure>
    <time_frame>Baseline, 24 weeks(End of trial)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidents of side effects between groups</measure>
    <time_frame>Baseline, 24 weeks(End of trial)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Hypertension</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Group T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group T+M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan plus Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C+M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan pus Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A+M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine plus Metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan plus Metformin</intervention_name>
    <description>Telmisartan 80mg 1/d, Metformin 250mg 2/d</description>
    <arm_group_label>Group T+M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>Telmisartan 80mg 1/d</description>
    <arm_group_label>Group T</arm_group_label>
    <other_name>Telmisartan Alone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan</intervention_name>
    <description>Candesartan 8mg daily</description>
    <arm_group_label>Group C</arm_group_label>
    <other_name>Candesartan Alone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan plus Metformin</intervention_name>
    <description>Candesartan 8mg 1/d Metformin 250mg 2/d</description>
    <arm_group_label>Group C+M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Amlodipine 5mg 1/d</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Amlodipine alone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine plus Metformin</intervention_name>
    <description>Amlodipine 5mg 1/d, Metformin 250mg 2/d</description>
    <arm_group_label>Group A+M</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Grade 1 or 2 hypertension: 140mmHg≤SBP&lt;180mmHg, and/or 90mmHg≤DBP&lt;110mmHg

          -  Waist circumference higher than 90cm in men, 80cm in women

        Exclusion Criteria:

          -  Diabetes

          -  Grade 3 hypertension: SBP≥180mmHg, or DBP≥110mmHg

          -  known allergy or hypersensitivity to trial drugs

          -  Myocardial infarction or cerebrovascular accident in the year preceding the trial

          -  Clinical Congestive Heart Failure

          -  History of hepatitis or cirrhosis

          -  History of kidney disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiming Zhu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The third hospital affiliated to the Third Military Medical University. China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhiming Zhu, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>The third hospital affiliated to the Third Military Medical University. China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The third hospital affiliated to the Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>He H, Zhao Z, Chen J, Ni Y, Zhong J, Yan Z, Li Y, Liu D, Pletcher MJ, Zhu Z. Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial. J Hypertens. 2012 Jul;30(7):1430-9. doi: 10.1097/HJH.0b013e328353e249.</citation>
    <PMID>22525206</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2007</study_first_submitted>
  <study_first_submitted_qc>October 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2007</study_first_posted>
  <last_update_submitted>May 12, 2013</last_update_submitted>
  <last_update_submitted_qc>May 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Zhiming Zhu</investigator_full_name>
    <investigator_title>Director of Dept. of Hypertension &amp; Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Abdominal obesity</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

